Oligodendroglioma - Pipeline Review, H2 2016

Date: September 21, 2016
Pages: 116
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OE358DFEAECEN
Leaflet:

Download PDF Leaflet

Oligodendroglioma - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Oligodendroglioma - Pipeline Review, H2 2016’, provides an overview of the Oligodendroglioma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Oligodendroglioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of Oligodendroglioma
  • The report reviews pipeline therapeutics for Oligodendroglioma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Oligodendroglioma therapeutics and enlists all their major and minor projects
  • The report assesses Oligodendroglioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Oligodendroglioma
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Oligodendroglioma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Oligodendroglioma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Oligodendroglioma Overview
Therapeutics Development
Pipeline Products for Oligodendroglioma - Overview
Pipeline Products for Oligodendroglioma - Comparative Analysis
Oligodendroglioma - Therapeutics under Development by Companies
Oligodendroglioma - Therapeutics under Investigation by Universities/Institutes
Oligodendroglioma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Oligodendroglioma - Products under Development by Companies
Oligodendroglioma - Products under Investigation by Universities/Institutes
Oligodendroglioma - Companies Involved in Therapeutics Development
AngioChem Inc.
Axelar AB
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cavion LLC
Celldex Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Millennium Pharmaceuticals Inc
Novartis AG
Pfizer Inc.
Tocagen Inc.
Oligodendroglioma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
afatinib dimaleate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alisertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AXL-1717 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevacizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDX-1401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Gliomas - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNX-2401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flucytosine + TBio-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flucytosine ER + vocimagene amiretrorepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
irinotecan hydrochloride + TBio-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mibefradil dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nilotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
p28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
paclitaxel trevatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligodendroglioma - Dormant Projects
Oligodendroglioma - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 116

LIST OF TABLES

Number of Products under Development for Oligodendroglioma, H2 2016
Number of Products under Development for Oligodendroglioma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Oligodendroglioma - Pipeline by AngioChem Inc., H2 2016
Oligodendroglioma - Pipeline by Axelar AB, H2 2016
Oligodendroglioma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Oligodendroglioma - Pipeline by Bristol-Myers Squibb Company, H2 2016
Oligodendroglioma - Pipeline by Cavion LLC, H2 2016
Oligodendroglioma - Pipeline by Celldex Therapeutics, Inc., H2 2016
Oligodendroglioma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Oligodendroglioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Oligodendroglioma - Pipeline by Novartis AG, H2 2016
Oligodendroglioma - Pipeline by Pfizer Inc., H2 2016
Oligodendroglioma - Pipeline by Tocagen Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Oligodendroglioma - Dormant Projects, H2 2016
Oligodendroglioma - Discontinued Products, H2 2016 114

LIST OF FIGURES

Number of Products under Development for Oligodendroglioma, H2 2016
Number of Products under Development for Oligodendroglioma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Oligodendroglioma - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 132 pages
Mild Psoriasis - Pipeline Review, H2 2015 US$ 1,700.00 Nov, 2015 · 48 pages

Ask Your Question

Oligodendroglioma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: